'Statin' diaporamas de présentation

Diagnostic Evaluation of the Hypertensive Patient- How much is enough?

Diagnostic Evaluation of the Hypertensive Patient- How much is enough?. Thomas Pickering MD, DPhil Behavioral Cardiovascular Health and Hypertension Program Columbia Presbyterian Medical Center New York.

839 views • 73 slides

Mancini et al, DOI: dx.doi/10.1016/j.cjca.2016.01.003

Diagnosis, Prevention and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016).

1.19k views • 70 slides

Drugs and Labs, what needs to be monitored?

724 views • 59 slides

Franciscan St. Anthony Health Michigan City, IN

Franciscan St. Anthony Health Michigan City, IN. St. Margaret Health. Hammond. St. Anthony Health. Michigan City. 80. 80. 90. 90. St. Anthony Health. Crown Point. 65. St. Francis Health. Indianapolis. 65. Franciscan Health Services, Inc. Franciscan Alliance Corporate Office.

646 views • 44 slides

Welcome Ask The ExpertsMarch 24-27

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary ... Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary ...

735 views • 38 slides

The New Lipid Guidelines

The New Lipid Guidelines. What you need to know Paul J Kovack, DO, FACOI, FACC. Overview. NHLBI ACC/AHA First new guidelines since ATP III guideline update in 2004 Review the most important statements or changes presented in these guidelines No longer have therapeutic targets

1.52k views • 38 slides

582 views • 37 slides

565 views • 34 slides

Baseline characteristics of HPS participants by prior diabetes

Baseline characteristics of HPS participants by prior diabetes. HPS: Baseline lipids (mmol/L) and apolipoproteins (g/L) by prior diabetes. HPS: Baseline lipids (mg/dL) and apolipoproteins (g/L) by prior diabetes. HPS: FACTORIAL TREATMENT COMPARISONS.

369 views • 25 slides

Economic evaluation of MRC/BHF Heart Protection Study

Economic evaluation of MRC/BHF Heart Protection Study. Heart Protection Study Collaborative Group University of Oxford UK. HPS: Eligibility criteria. Increased risk of CHD death due to prior disease: Myocardial infarction or other CHD; Occlusive disease of non-coronary arteries; or

552 views • 23 slides

CM Ballantyne, 1 JS Raichlen, 2 SJ Nicholls, 3 R Erbel, 4

Effect of Rosuvastatin Therapy on Coronary Artery Stenosis Assessed by Quantitative Coronary Angiography in ASTEROID. CM Ballantyne, 1 JS Raichlen, 2 SJ Nicholls, 3 R Erbel, 4 J-C Tardif, 5 SJ Brener, 3 VA Cain, 2 SE Nissen, 3 For the ASTEROID Investigators.

394 views • 23 slides

STATINS ANTI-CHOLESTEROL AGENTS

Patrick: An Introduction to Medicinal Chemistry 4e. Case Study 1. STATINS ANTI-CHOLESTEROL AGENTS. 1. Cholesterol. Notes Important in biosynthesis and cell membrane structure Excess cholesterol leads to cardiovascular disease

916 views • 22 slides

Clinical Biochemistry

Clinical Biochemistry. FAQ for GP Trainees. Dr Mourad Labib Consultant Chemical Pathologist DGOH NHS Foundation Trust. July 2009. Common scenarios How best to investigate common problems Gold Standard investigations Advances in Clinical Biochemistry. Plan.

1.04k views • 21 slides

308 views • 15 slides

Tara Dall , MD Advanced Lipidology Delafield, Wisconsin

Advances in Statin Therapy: Expert Recommendations for Optimizing the Management of Dyslipidemia in the Clinically Complex Patient. Tara Dall , MD Advanced Lipidology Delafield, Wisconsin Diplomate , American Board of Clinical Lipidology.

360 views • 11 slides

345 views • 9 slides

Statin Safety: Key Conclusions and Recommendations of the NLA

Statin Safety: Key Conclusions and Recommendations of the NLA. Conclusions of the NLA Safety Task Force for Muscle Safety. Myopathy and rhabdomyolysis are associated with statin therapy, as a class effect Elevated creatine kinase (CK) levels may indicate statin-induced muscle damage

254 views • 7 slides

Factors That Increase the Risk of Myopathy in People Taking Statins

147 views • 7 slides

Insights from clinical trials : The unassailable case for LDL-c lowering

Master class: Exploring the clinical innovations in lipid management? June 4-5, 2010, Barcelona. Insights from clinical trials : The unassailable case for LDL-c lowering. Kausik Ray, MD St Georges University London, United Kingdom. Prof. Kausik Ray: Biography.

170 views • 6 slides

UCLA Comprehensive Atherosclerosis Treatment Program Medication Goals

Front. Back. UCLA Comprehensive Atherosclerosis Treatment Program Medication Goals All patients with coronary, other vascular disease, or diabetes treated with aspirin and/or clopidogrel*

126 views • 2 slides